Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced its financial results for the fiscal year ended December 31, 2025, highlighting a strengthened financial position with a year-end cash balance of $14.7 million, providing a runway into mid-2028. The company received FDA Fast Track designation for its drug stenoparib, aimed at treating advanced ovarian cancer, which allows for accelerated development and regulatory engagement. Notably, durable clinical benefits were observed in ongoing studies, with some patients remaining on treatment for nearly 30 months. The company also expanded its development efforts beyond ovarian cancer, launching a Phase 2 combination study of stenoparib and temozolomide for recurrent small cell lung cancer, funded by the U.S. Veterans Administration. Allarity's CEO, Thomas Jensen, emphasized the company's commitment to advancing stenoparib towards pivotal trials and FDA approval, while also reducing cash used in operations by approximately $2.4 million. The financial results showed a net loss of $11.2 million for 2025, an improvement from $25.1 million in 2024, reflecting operational efficiencies and cost discipline. The company generated $320,000 in revenue during the fourth quarter, marking its first revenue since 2024. Allarity's strategic initiatives and clinical advancements position it favorably for future growth and shareholder value.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.